ReviewTherapeutic advances in gastroenterology2020
Interplay of intestinal microbiota and mucosal immunity in inflammatory bowel disease: a relationship of frenemies.
Review in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.Gut microbes · 2023Pooled it
- Reactivity of Autologous Serum IgG to Gut Microbes in Pediatric Ulcerative Colitis.International journal of molecular sciences · 2025Article
- Challenges of concurrent HIV infection in the course and management of Crohn's disease.Journal of medicine and life · 2025Review
- Treatment with omega-3-rich fish oil enhances host defense and reduces intestinal colonization by diarrheagenic Escherichia coli.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Lactic Acid Bacteria-Gut-Microbiota-Mediated Intervention towards Inflammatory Bowel Disease.Microorganisms · 2024Review
- Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease.Precision clinical medicine · 2024Review
- Sijunzi decoction alleviates inflammation and intestinal epithelial barrier damage and modulates the gut microbiota in ulcerative colitis mice.Frontiers in pharmacology · 2024Article
- Association between dementia risk and ulcerative colitis, with and without colectomy: a Swedish population-based register study.BMJ open · 2023Article
- The latest breakthrough on genetic characteristics of inflammatory bowel disease in Chinese and other East Asian ancestries.Precision clinical medicine · 2023Article
- Comparison of Metagenomics and Metatranscriptomics Tools: A Guide to Making the Right Choice.Genes · 2022Article
- Acute appendicitis and ulcerative colitis: a population-based sibling comparison study.BMJ open gastroenterology · 2022Article
- Effect of Early PathogenicFrontiers in cellular and infection microbiology · 2022Article
- Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases.Precision clinical medicine · 2021Review
- Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel, Switzerland) · 2021Review
- Processing Matters in Nutrient-Matched Laboratory Diets for Mice-Microbiome.Animals : an open access journal from MDPI · 2021Article
- Dysregulation of CD177Gut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are chronic inflammatory disorders of the gastrointestinal tract. With in-depth studies on the mechanisms of the initiation and development of IBD, increasing lines of evidence have focused on the intestinal microbiota in the pathogenesis of IBD. The imbalance between the host and intestinal microbiota induces dysregulated immune response in intestinal mucosa and plays a pivotal role in the initiation of disease and ongoing bowel destruction. This review focuses on recent advances in intestinal microbiota regulation of mucosal immune response as well as novel approaches based on intestinal microbiota alterations in the diagnosis and evaluation of therapeutic response in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.